NCT02078674View on ClinicalTrials.gov

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

610

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Influenza (Pandemic)
Interventions
BIOLOGICAL

Monovalent Avian Influenza VLP (H7N9)

BIOLOGICAL

Matrix-M1™ adjuvant

BIOLOGICAL

Placebo

Trial Locations (5)

13760

Regional Clinical Research, Inc., Endwell

29464

Coastal Carolina Research, Mt. Pleasant

33143

Miami Research Associates, Miami

83642

Advanced Clinical Research, Meridian

94598

Diablo Clinical Research, Walnut Creek

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Novavax

INDUSTRY

NCT02078674 - A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant | Biotech Hunter | Biotech Hunter